The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Neoplasms, Second Primary

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Neoplasms, Second Primary


High impact information on Neoplasms, Second Primary


Chemical compound and disease context of Neoplasms, Second Primary

  • RESULTS: In the Stockholm Trial, there was a statistically significant (P = .008) reduction in the incidence of second primary cancers in the contralateral breast among the tamoxifen-treated patients [11].
  • No second malignancies were observed in patients given ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) with or without RT [12].
  • Since our analysis supports the evidence of a major role played by alkylating agents, procarbazine, and RT in inducing second malignancies, regimens not containing there drugs or their administration through treatments of different intensity warrant careful consideration [12].
  • PATIENTS AND METHODS: We reviewed the long-term follow-up data for 2,014 patients treated on National Cancer Institute Group C protocols with fludarabine for relapsed and refractory CLL and with DCF and CdA for HCL using a Second Cancer Report. The numbers of observed and expected secondary tumors were compared [13].
  • None of 224 patients on surveillance strategy (with or without retroperitoneal lymph node dissection [RPLND]) developed a second neoplasm, compared with four of 413 patients (0.97%; 95% CI, 0 to 1.9) after cisplatin-based chemotherapy (not significant) and nine of 332 patients (2.7%; 95% CI, 0.9 to 4.5) after radiotherapy (P = .02) [14].

Biological context of Neoplasms, Second Primary


Anatomical context of Neoplasms, Second Primary


Gene context of Neoplasms, Second Primary


Analytical, diagnostic and therapeutic context of Neoplasms, Second Primary


  1. Re: second cancers after adjuvant tamoxifen therapy for breast cancer. Atkins, C.D. J. Natl. Cancer Inst. (1996) [Pubmed]
  2. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. Tucker, M.A., Murray, N., Shaw, E.G., Ettinger, D.S., Mabry, M., Huber, M.H., Feld, R., Shepherd, F.A., Johnson, D.H., Grant, S.C., Aisner, J., Johnson, B.E. J. Natl. Cancer Inst. (1997) [Pubmed]
  3. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. Fornander, T., Hellström, A.C., Moberger, B. J. Natl. Cancer Inst. (1993) [Pubmed]
  4. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. Frebourg, T., Kassel, J., Lam, K.T., Gryka, M.A., Barbier, N., Andersen, T.I., Børresen, A.L., Friend, S.H. Proc. Natl. Acad. Sci. U.S.A. (1992) [Pubmed]
  5. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Flinn, I.W., Kopecky, K.J., Foucar, M.K., Head, D., Bennett, J.M., Hutchison, R., Corbett, W., Cassileth, P., Habermann, T., Golomb, H., Rai, K., Eisenhauer, E., Appelbaum, F., Cheson, B., Grever, M.R. Blood (2000) [Pubmed]
  6. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. Malkin, D., Jolly, K.W., Barbier, N., Look, A.T., Friend, S.H., Gebhardt, M.C., Andersen, T.I., Børresen, A.L., Li, F.P., Garber, J. N. Engl. J. Med. (1992) [Pubmed]
  7. Association between thymoma and second neoplasms. Welsh, J.S., Wilkins, K.B., Green, R., Bulkley, G., Askin, F., Diener-West, M., Howard, S.P. JAMA (2000) [Pubmed]
  8. Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells. Boyle, J.O., Langenfeld, J., Lonardo, F., Sekula, D., Reczek, P., Rusch, V., Dawson, M.I., Dmitrovsky, E. J. Natl. Cancer Inst. (1999) [Pubmed]
  9. Re: second cancers after adjuvant tamoxifen therapy for breast cancer. Rutqvist, L.E. J. Natl. Cancer Inst. (1996) [Pubmed]
  10. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. Travis, L.B., Curtis, R.E., Glimelius, B., Holowaty, E.J., Van Leeuwen, F.E., Lynch, C.F., Hagenbeek, A., Stovall, M., Banks, P.M., Adami, J. J. Natl. Cancer Inst. (1995) [Pubmed]
  11. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. Rutqvist, L.E., Johansson, H., Signomklao, T., Johansson, U., Fornander, T., Wilking, N. J. Natl. Cancer Inst. (1995) [Pubmed]
  12. Absence of treatment-induced second neoplasms after ABVD in Hodgkin's disease. Valagussa, P., Santoro, A., Fossati Bellani, F., Franchi, F., Banfi, A., Bonadonna, G. Blood (1982) [Pubmed]
  13. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. Cheson, B.D., Vena, D.A., Barrett, J., Freidlin, B. J. Clin. Oncol. (1999) [Pubmed]
  14. Secondary neoplasms following treatment of malignant germ cell tumors. Bokemeyer, C., Schmoll, H.J. J. Clin. Oncol. (1993) [Pubmed]
  15. Kaposi's sarcoma with a non-Hodgkin's lymphoma. Its association in a male homosexual with human T-cell lymphotropic virus type III infection. Katner, H.P., Pankey, G.A., Flaum, M.A., Dalovisio, J.R., Cortez, L.M., DeShazo, R.D. Arch. Intern. Med. (1986) [Pubmed]
  16. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Chan, H.S., DeBoer, G., Thiessen, J.J., Budning, A., Kingston, J.E., O'Brien, J.M., Koren, G., Giesbrecht, E., Haddad, G., Verjee, Z., Hungerford, J.L., Ling, V., Gallie, B.L. Clin. Cancer Res. (1996) [Pubmed]
  17. Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferon. Beran, M., Andersson, B., Kantarjian, H., Keating, M., Rios, A., McCredie, K.B., Freireich, E.J., Gutterman, J. Leukemia (1987) [Pubmed]
  18. Mutagen sensitivity as a biomarker for second primary tumors after head and neck squamous cell carcinoma. Cloos, J., Leemans, C.R., van der Sterre, M.L., Kuik, D.J., Snow, G.B., Braakhuis, B.J. Cancer Epidemiol. Biomarkers Prev. (2000) [Pubmed]
  19. No germline mutations in CDKN2A (p16) in patients with squamous cell cancer of the head and neck and second primary tumours. Jefferies, S., Edwards, S.M., Hamoudi, R.A., A'Hern, R., Foulkes, W., Goldgar, D., Eeles, R. Br. J. Cancer (2001) [Pubmed]
  20. Dietary antioxidant intake in patients at risk for second primary cancer. Steward, D.L., Wiener, F., Gleich, L.L., Falciglia, G. Laryngoscope (2003) [Pubmed]
  21. No evidence of association of methylenetetrahydrofolate reductase polymorphism with occurrence of second neoplasms after treatment of childhood leukemia. Jazbec, J., Kitanovski, L., Aplenc, R., Debeljak, M., Dolzan, V. Leuk. Lymphoma (2005) [Pubmed]
  22. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Adams, M.J., Lipshultz, S.E. Pediatric blood & cancer. (2005) [Pubmed]
  23. BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients. Rogozińska-Szczepka, J., Utracka-Hutka, B., Grzybowska, E., Maka, B., Nowicka, E., Smok-Ragankiewicz, A., Zientek, H., Steffen, J., Wojciechowska-Łacka, A. Ann. Oncol. (2004) [Pubmed]
  24. DNA repair gene polymorphisms and risk of second primary neoplasms and mortality in oral cancer patients. Gal, T.J., Huang, W.Y., Chen, C., Hayes, R.B., Schwartz, S.M. Laryngoscope (2005) [Pubmed]
  25. BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Shih, H.A., Nathanson, K.L., Seal, S., Collins, N., Stratton, M.R., Rebbeck, T.R., Weber, B.L. Clin. Cancer Res. (2000) [Pubmed]
  26. XPD polymorphism and risk of subsequent cancer in individuals with nonmelanoma skin cancer. Brewster, A.M., Alberg, A.J., Strickland, P.T., Hoffman, S.C., Helzlsouer, K. Cancer Epidemiol. Biomarkers Prev. (2004) [Pubmed]
  27. Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment. Kampmeier, P., Spielberger, R., Dickstein, J., Mick, R., Golomb, H., Vardiman, J.W. Blood (1994) [Pubmed]
  28. Recurrent prolactinoma and meningioma following irradiation and bromocriptine treatment. Kolodny, J., Dluhy, R.G. Am. J. Med. (1985) [Pubmed]
  29. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. Grossfeld, G.D., Latini, D.M., Lubeck, D.P., Mehta, S.S., Carroll, P.R. J. Urol. (2003) [Pubmed]
  30. Second cancers after prolonged adjuvant thiotepa for operable carcinoma of the breast. Kardinal, C.G., Donegan, W.L. Cancer (1980) [Pubmed]
WikiGenes - Universities